Larimar Therapeutics (LRMR) Files 8-K: Q2 2025 Results Furnished

Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2025, via a press release furnished on August 14, 2025.

Rhea-AI Filing Summary

Larimar Therapeutics, Inc. announced its financial results and operational highlights for the second quarter ended June 30, 2025, via a press release furnished on August 14, 2025. The Current Report does not include the numerical results in-line but references that the press release is provided as Exhibit 99.1.

The company also posted an updated corporate slide presentation on its website, furnished as Exhibit 99.2, which company representatives will use in investor and analyst meetings. The filing states the furnished materials are intended to be "furnished" and not "filed" under the Exchange Act.

Insights

Financial Analyst

TL;DR The 8-K notifies investors that Q2 2025 results were released, but contains no figures here, limiting immediate assessment.

The report confirms Larimar announced its second-quarter results for the period ended June 30, 2025, and furnished the related press release (Exhibit 99.1) and an updated investor presentation (Exhibit 99.2). Because the current report text does not include revenue, net income, cash position, guidance, or other metrics, this filing is informational and routine; material analysis requires review of the attached exhibits.

Investor Relations Specialist

TL;DR Larimar furnished its Q2 2025 press release and updated slides on August 14, 2025; materials are posted and will be used in meetings.

The filing documents proactive communication: a press release announcing second-quarter results and an updated corporate presentation posted to the company website. The filing explicitly states these exhibits are "furnished" rather than "filed," which clarifies their regulatory status. The update indicates active investor outreach but, in this document, provides no financial detail.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 07:02 AM Learn about SEC filing dates

false000137469000013746902025-08-142025-08-14

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2025

Larimar Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-36510	20-3857670
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Three Bala Plaza East
Bala Cynwyd, Pennsylvania				19004
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (844) 511-9056

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		LRMR		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, Larimar Therapeutics, Inc. (the “Company”) announced its financial results and operational highlights for the second quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

On August 14, 2025, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Below is a list of exhibits included with this Current Report on Form 8-K.

Exhibit No.		Document
99.1		Press Release issued by Larimar Therapeutics, Inc. on August 14, 2025*
99.2		Larimar Therapeutics, Inc. Corporate Presentation, dated August 14, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Larimar Therapeutics, Inc.
Date:	August 14, 2025	By:	/s/ Carole S. Ben-Maimon, M.D.
			Name: Carole S. Ben-Maimon, M.D. Title: President and Chief Executive Officer